Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Acta Cardiol ; : 796-802, 2024 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-38511517

RESUMO

OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin are antidiabetic drugs that have recently been reported to have cardio-protective action; however, their effect on cardiac structure and function in heart failure with reduced ejection fraction (HFrEF) has not yet been determined. This study evaluates the efficacy of empagliflozin on left ventricular (LV) volumes in type 2 diabetes or prediabetes patients with HFrEF. METHODS: This randomised, double-blind, trial study was conducted on 104 patients with type 2 diabetes or prediabetes with HFrEF referred to Imam Khomeini and Golestan hospitals in Ahvaz, Iran. The patients were randomised to receive empagliflozin (10 mg once daily) in addition to standard treatments of HFrEF or receive only standard treatments (control group) for six months. During the six months of follow-up, changes in LV volumes, LVEF, hospitalisation for heart failure (HF) were evaluated. RESULTS: Empagliflozin reduced LVEDVI and LVESVI by 10.0 and 8.0 mL/m2 (p < 0.0001). Furthermore, a significant increase in LVEF was observed in the empagliflozin group (p < 0.0001) without any significant change in the control group (p = 0.389). The hospitalisation rate was lower in the empagliflozin group than the control group (3.8% vs. 23.1%; p = 0.008). CONCLUSIONS: Empagliflozin is effective in reducing LV volumes and hospitalisation rate in patients with type 2 diabetes and prediabetes and HFrEF. Therefore, treatment with empagliflozin for six months was associated with a significant reduction in adverse cardiovascular outcomes in these patients.

2.
Int J Endocrinol Metab ; 21(1): e130434, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36945345

RESUMO

Background: Accurate evaluation of response to treatment in differentiated thyroid cancer (DTC) is the sine qua non of preventing over-treatment in low-risk patients and implementing appropriate interventions in high-risk individuals. Objectives: This study aimed to assess the response to therapy in DTC patients based on dynamic stratification method. Methods: In this cross-sectional study, 154 medical records of subjects with DTC (with at least 6 months after total thyroidectomy) and referred to endocrinology clinics in Ahvaz, Iran, from April 2020 to May 2021 were examined. Patients were stratified according to a dynamic risk stratification system (informed by their specific clinical, histopathological, and ultrasonography findings, and other diagnostic imagines) into four groups: Excellent response (ER), indeterminate response (IR), biochemical incomplete response (BIR), and structural incomplete response (SIR). Results: For a mean follow-up period of 28.59 months, excellent response to treatment was observed in 92 patients (59.7%), indeterminate response to treatment was found in 32 patients (20.8%), biochemical incomplete response was detected in 2 patients (1.3%), and structural incomplete response was seen in 28 patients (18.2%). In the group with low risk of recurrence, ER and IR were observed in 79.2% and 15.6% of the patients, respectively (P < 0.0001). In the group with an intermediate risk of recurrence, ER was found in 32% of the patients, while IR and SIR + BIR were seen in 34% and 34% of the patients, respectively (P < 0.0001). No cases of ER or IR were observed in the group with high risk (P = 0.001). Conclusions: In sum, response to treatment significantly varied based on dynamic risk stratification, with ER being highest in the low-risk group, less likely in moderate risk group, and undetected in the high-risk group.

3.
Iran J Nurs Midwifery Res ; 25(3): 224-231, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32724768

RESUMO

BACKGROUND: Physical activity among women with type 2 Diabetes Mellitus (DM) is an undesirable level. This study aimed to determine the effect of a training program based on the Health Promotion Model (HPM) on physical activity in women with type 2 DM. MATERIALS AND METHODS: This randomized clinical trial was performed on 128 women with type 2 DM, who were randomly assigned to control and intervention groups. Data were collected using the Baecke Physical Activity Questionnaire (BPAQ) and a researcher-made questionnaire designed based on the HPM constructs before and 2 months after the intervention. The training was carried out in four sessions in the intervention group and the control group received regular education at the clinic. Data were analyzed using Chi-square, Fisher's exact test, paired t-test, independent t-test, and Mann-Whitney and Wilcoxon tests in Statistical Package for the Social Sciences (SPSS) software. RESULTS: The findings showed that the mean [Standard Deviation (SD)] of physical activity in the intervention and control groups before the intervention was 6.52 (0.86) and 6.56 (1.07), respectively, and there was no significant difference between the groups (p = 0.95). However, after the intervention, the mean (SD) of physical activity in the intervention and control groups was 8.04 (0.92) and 6.33 (1.60), respectively, which showed a significant difference (t126= 9.71, p < 0.001). CONCLUSIONS: The findings of this study revealed that the training program based on the HPM has a positive effect on improving physical activity in women with type 2 DM.

4.
J Res Med Sci ; 25: 37, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32582343

RESUMO

BACKGROUND: Weight management is an important strategy to prevent the consequences of obesity. The aim of the study was to compare the effect of yoga practice and energy-restricted diet on resting metabolic rate (RMR), anthropometric indices, and serum adiponectin and leptin in overweight and obese women. MATERIALS AND METHODS: Obese or overweight women were divided into two groups: yoga practicing and energy-restricted diet. Exercise trials consisted of 60-min Hatha yoga equal to 200 kilocalories (kcal) combined with 300 kcal restriction per day, and an energy-restricted diet consisted of 500 kcal restriction per day. The intervention period for both the groups was 8 weeks. RMR, anthropometric indices, and serum adiponectin, leptin, and lipid profiles were measured at baseline and at the end of the study. RESULTS: RMR was increased in yoga but not in the diet group (P = 0.001). The level of adiponectin was increased in the yoga group compared with the diet (P = 0.035). The concentration of high-density lipoprotein-cholesterol was decreased in the diet group significantly but not in yoga (P = 0.006). The level of leptin was decreased in both the groups (P = 0.001), and there were no significant differences between the two groups. CONCLUSION: The findings of the study demonstrated the effect of yoga practicing on RMR, and serum adiponectin, in overweight and obese women. It seems yoga practice with less energy restriction compared with a common energy restriction diet and is more effective in weight management for those who are in weight loss programs.

5.
Eur J Sport Sci ; 20(10): 1355-1367, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31957555

RESUMO

Maintenance of the serum 25-hydroxyvitamin D (25-OH-D) concentration at recommended levels is essential due to its role in the regulation of anabolic hormones and athletic performance. However, the results of the clinical experiments in athletes are controversial. The present study aimed to investigate the effect of vitamin D3 supplement on serum levels of anabolic hormones, cortisol, anaerobic and aerobic performance in active males. In this double-blind, randomized controlled trial, 46 active males randomly assigned to vitamin D3 supplement (VDS; 2000 IU/day) or placebo for 12 weeks. The Wingate test, VO2max, and serum levels of 25-OH-D, Parathyroid hormone (PTH), total testosterone, growth hormone (GH), Insulin-like growth factor-1 (IGF-1), and cortisol were assessed. Subjects in the VDS group had a higher serum level of 25-OH-D (p = 0.004), VO2max (p = 0.016), and average power (p = 0.044) compared to the placebo at the end of the study. Also, lower levels of PTH (p = 0.004) and fatigue index (p < 0.001) were observed in VDS group at the end of the study. The serum cortisol levels were reduced significantly only in subjects with vitamin D deficiency in VDS group (p = 0.042). There was a significant reduction in serum testosterone levels in VDS group (p = 0.013). No change was indicated in serum levels of GH and IGF-1 in VDS group compared to the placebo (p > 0.05). The present study showed an improvement in aerobic capacity, anaerobic performance, and vitamin D status following vitamin D3 supplementation. However, more studies are required for the effect of vitamin D3 on serum concentration of anabolic hormones.


Assuntos
Colecalciferol/administração & dosagem , Hormônio do Crescimento/sangue , Hidrocortisona/sangue , Fator de Crescimento Insulin-Like I/análise , Hormônio Paratireóideo/sangue , Testosterona/sangue , Vitamina D/análogos & derivados , Aerobiose , Anaerobiose , Análise de Variância , Desempenho Atlético/fisiologia , Índice de Massa Corporal , Método Duplo-Cego , Exercício Físico , Fadiga/sangue , Humanos , Irã (Geográfico) , Masculino , Consumo de Oxigênio/fisiologia , Placebos/administração & dosagem , Estações do Ano , Fatores de Tempo , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Adulto Jovem
6.
Diabetes Metab Syndr ; 13(2): 1387-1391, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31336497

RESUMO

BACKGROUND: Type 2 diabetes has a high spread and growing process. Using appropriate food diets is among therapeutic approaches has been applied for diabetic patients. Soya utilization has shown effective results in controlling metabolic abnormalities of these patients. The aim of this study is to investigate the effects of soy nut on glycemic conditions, blood pressure, lipid profile, antioxidant effects and vascular endothelial function of these patients. METHODS: 70 patients with type 2 diabetes were randomly divided into two groups of the test (35 people) and control (35 people). The patients in the intervention group were subjected to 60 g soy nut diet as a part of daily protein for 8 weeks and the control group under the usual diet of diabetes. The fasting glucose, blood pressure, lipid profile, brachial blood flow, the level of serum E-Selectin and total antioxidant capacity in control and test group were assessed before and after diet. RESULTS: Consuming 60 g soy nut for 8 weeks significantly decreased the fasting blood glucose (P = 0.03), total serum cholesterol (P < 0.01), LDL-c (P = 0.01), and E-Selectin (P < 0.01) and increased the capacity of serum total antioxidants (P < 0.01), brachial blood flow (P < 0.01) but didn't have any significant effect on systolic/diastolic blood pressure, HDL-c, and TG. CONCLUSION: Soy nut utilization in the patients with type-2 diabetes can significantly improve the glycemic condition, increase brachial blood flow, decrease E-selectin (improvement of endothelial function), increase serum total antioxidants and lipid profile but has no significant effect on blood pressure and HDL-c.


Assuntos
Antioxidantes/metabolismo , Biomarcadores/análise , Doenças Cardiovasculares/prevenção & controle , Diabetes Mellitus Tipo 2/sangue , Endotélio Vascular/fisiopatologia , Glycine max/química , Nozes , Velocidade do Fluxo Sanguíneo , Artéria Braquial/fisiopatologia , Doenças Cardiovasculares/sangue , Estudos de Casos e Controles , Diabetes Mellitus Tipo 2/dietoterapia , Diabetes Mellitus Tipo 2/patologia , Selectina E/metabolismo , Endotélio Vascular/efeitos dos fármacos , Feminino , Seguimentos , Índice Glicêmico , Humanos , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Prognóstico , Fatores de Risco
7.
Diabetes Metab Syndr ; 13(3): 1833-1835, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31235102

RESUMO

AIMS: Diabetes mellitus is a metabolic disease that manifested as hyperglycemia due to the defect in secretion or function of insulin. This study aimed was to survey about frequency type I and II diabetes in newly diagnosed diabetic patients base on c-peptide and anti-glutamate acid decarboxylase (GAD) tests. MATERIALS & METHODS: This study was conducted as a prospective study on 70 diabetic patients aged 15-45 years old who referred to diabetes clinics in Ahvaz city during 2012-2014 and their diabetes was diagnosed for the first time, but their type of diabetes was not clinically definitive. Patients with anti-GAD positive and fasting C-peptide level of less than 0.65 were diagnosed as type I diabetes. Patients with anti-GAD negative fasting C-peptide level of greater than or equal to 0.65 were considered as type II diabetes. RESULTS: Eighty two patients (49 males and 33 females) with a mean age of 21.64 ±â€¯4.36 years (range 15-34) and a mean BMI of 22.05 ±â€¯4.41 kg/m2 (range 14-18) were studied. Twenty three patients (28.5%) had type I diabetes and 59 patients (71.95%) had type II diabetes. In patients with type I diabetes, the mean BMI was 24.86 ±â€¯2.36 kg/m2 and the number of patients with family history (56.22%) was higher. In type II diabetic patients, the number of women (62.71%) was higher than that of men. CONCLUSION: Anti-GAD test can be used as a predictive test for early diagnosis of disease and screening of people with a diagnosis of diabetes based on the type of diabetes.


Assuntos
Biomarcadores/sangue , Glicemia/análise , Peptídeo C/sangue , Diabetes Mellitus Tipo 1/epidemiologia , Diabetes Mellitus Tipo 2/epidemiologia , Adolescente , Adulto , Autoanticorpos/sangue , Autoanticorpos/imunologia , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/diagnóstico , Feminino , Seguimentos , Glutamato Descarboxilase/imunologia , Humanos , Irã (Geográfico)/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Prognóstico , Estudos Prospectivos , Adulto Jovem
8.
Int J Prev Med ; 9: 86, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30450169

RESUMO

BACKGROUND: An appropriate snack for patients with diabetes mellitus should be considered to help them in their treatment due to their hard administrative diet. This study was conducted to evaluate the effect of dark chocolate on inflammatory markers, serum adiponectin, and certain biochemical factors in patients with type 2 diabetes (T2D). METHODS: This study was a randomized parallel clinical trial. Thirty grams of 84% dark chocolate, along with therapeutic lifestyle changes (TLCs) guidelines, were administrated to patients with T2D. Control group received only TLC guidelines. The intervention period was 8 weeks. Twenty-one subjects in dark chocolate and 23 subjects in control group completed the study. Fasting blood samples were collected before and after the intervention period and inflammatory markers, biochemical factors, and adiponectin levels were assessed. RESULTS: Fasting blood sugar, hemoglobin A1C, low-density lipoprotein and triglyceride levels declined significantly in the dark chocolate group and this decrease was significant between the intervention and control groups. Tumor necrosis factor-alpha, interleukin-6, and high sensitive C-reactive protein were significantly decreased in the dark chocolate group. Adiponectin levels were not significantly different between the two groups. CONCLUSIONS: In this study subjects who received dark chocolate along with TLC guidelines had lower levels of inflammatory markers such as hs-CRP, TNF-α, and IL-6, compared with the subjects who were devoid of dark chocolate and followed only the TLC guidelines. Other studies should be conducted to evaluate the most effective and administrative dosage of dark chocolate as a snack along with the common treatment of diabetes.

9.
Diabetes Metab Syndr ; 12(5): 721-725, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29699949

RESUMO

AIMS: Early identification of at-risk groups is an important step in preventing gestational diabetes and its subsequent side effects. This study aimed to evaluate the risk factors of gestational diabetes based on the International Association of Diabetes and Pregnancy Study Groups criteria in Ahvaz. MATERIAL AND METHODS: In a cross-sectional case control study, 520 pregnant women involving life after gestational diabetes Ahvaz cohort study (LAGAs) were investigated for risk factors of gestational diabetes mellitus. RESULT: The prevalence of overweight and obesity were 40% and25.8% in the GMD group and in 35.8% and 16.2% in the control group respectively (p = 0.002). According to NCEP-ATP III criteria, 16.9% of women with GDM and 6.9% of mothers in the control group had metabolic syndrome in first visit of pregnancy (p < 0.001. Logistic regression showed that there is a significant relationship between maternal age[OR = 1.05(95% CI, 1.01-1.10)] (p = 0.01), previous GDM [OR = 5.60(95% CI, 2.21-14.18)] (p = 0.001), positive family history of diabetes[OR = 1.86(95% CI, 1.19-2.94)] (p = 0.006), pre-pregnancy BMI [OR = 1.05(95% CI, 1.007-1.11)] (p = 0.04) and metabolic syndrome in first visit of pregnancy[OR = 2.34 (95% CI, 1.038-5.30)] (p = 0.04) with GDM. CONCLUSION: Factors including maternal age, previous GDM, family history of diabetes, pre-pregnancy BMI reported in previous studies around the world. A significant association between metabolic syndrome in the first visit of pregnancy and GDM is novel finding of this study. Therefore screening of pre-pregnancy metabolic syndrome in women at risk of gestational diabetes is recommended.


Assuntos
Índice de Massa Corporal , Diabetes Gestacional/diagnóstico , Diabetes Gestacional/epidemiologia , Sobrepeso/diagnóstico , Sobrepeso/epidemiologia , Vigilância da População , Adulto , Fatores Etários , Estudos de Casos e Controles , Estudos de Coortes , Estudos Transversais , Diabetes Gestacional/fisiopatologia , Feminino , Humanos , Irã (Geográfico)/epidemiologia , Obesidade/diagnóstico , Obesidade/epidemiologia , Obesidade/fisiopatologia , Sobrepeso/fisiopatologia , Gravidez , Estudos Prospectivos , Fatores de Risco
10.
Diabetes Metab Syndr ; 12(3): 317-323, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29289537

RESUMO

AIMS: This study aimed to determine the prevalence rate of metabolic syndrome and its potential risk factors, 6-12 weeks postpartum in women with GDM compared to women with normal glucose tolerance. METHODS: LAGAs is an ongoing population-based prospective cohort study that started in March 2015 in Ahvaz, Iran. During 11 months of study progression, 176 women with GDM pregnancy and 86 healthy women underwent a fasting glucose test, 75-g OGTT and fasting lipid tests at 6-12 weeks postpartum. GDM was defined based on IADPSG criteria. Postpartum glucose intolerance was defined according to ADA criteria and metabolic syndrome using 2 sets of criteria. RESULTS: The overall rate of metabolic syndrome at 6-12 weeks postpartum was 16% by NCEP-ATP III criteria (18.2% in women with GDM and 11.6% in controls) and 19.1% by IDF criteria (21% in women with gestational diabetes and 15.1% in controls). Pre-pregnancy overweight or obesity, (OR 1.89, 95% CI: 1.05-3.38, P = .03), pregnancy systolic blood pressure (OR 1.03, 95% CI: 1.008-1.52, P = .006) and requiring insulin or metformin (OR 3.08, 95% CI: 1.25-7.60, P = 0.01), were associated risk factors for the presence of MetS in GDM-exposed women. In women with normal glucose during pregnancy, pre-pregnancy BMI ≥25 kg/m2 was a risk factor of metabolic syndrome (OR 2.82, 95% CI: 1.11-7.15, P = .02). CONCLUSION: The rate of metabolic syndrome in women with or without GDM at 6-12 weeks postpartum is high particularly in women with high BMI. An early postpartum prevention and screening program for cardiovascular risk factors is important for women with GDM.


Assuntos
Diabetes Gestacional/fisiopatologia , Intolerância à Glucose , Síndrome Metabólica/epidemiologia , Período Pós-Parto , Adulto , Estudos de Casos e Controles , Feminino , Seguimentos , Teste de Tolerância a Glucose , Humanos , Gravidez , Prevalência , Prognóstico , Estudos Prospectivos , Fatores de Risco
11.
Diabetes Metab Syndr ; 11 Suppl 2: S703-S712, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28571777

RESUMO

AIMS: Rate of postpartum screening and progression to glucose intolerance (diabetes and/or pre-diabetes) in Asian women with prior GDM and risk factors of diversion to abnormal glucose tolerance were reviewed. MATERIALS AND METHODS: We searched Pub Med, Cochrane Library, Web of Science, EMBASE, and Ovid data base. About 1300 studies were screened and 27 articles were selected. Meta-analysis using Comprehensive Meta -Analysis software was conducted. All results were reported at the pooled ORs and 95% CI. Quantitative heterogeneity (I2) was assessed. To estimate the variances between studies, the statistical method "tau-squared" was applied. Statistical models like fixed effect or Mantel-Haenszel, and random effect (REM) or Dersimonian-laird were used for the analysis and integration of results. RESULTS: Rate of glucose testing ranged from 13.1% to 81.9%. Prevalence of pre-diabetes was 3.9%-50.9%. Diabetes was reported in 2.8%-58% of women with history of gestational diabetes based on length of follow-up. Factor associated with postpartum diabetes mellitus included family History of diabetes mellitus, gestational age at diagnosis of GDM, insulin use during pregnancy and pre-pregnancy BMI. CONCLUSIONS: Rate of postpartum screening in most of the Asian countries population is sub-optimal, in spite of high rate of glucose intolerance in this high risk group of women. Risk factors of progression to pre-diabetes and diabetes are similar to previous reported in developed countries.


Assuntos
Glicemia/análise , Diabetes Gestacional/fisiopatologia , Intolerância à Glucose/epidemiologia , Programas de Rastreamento/métodos , Período Pós-Parto , Ásia/epidemiologia , Progressão da Doença , Feminino , Humanos , Gravidez , Fatores de Risco
12.
J Diabetes Res ; 2017: 9786436, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28491872

RESUMO

Background. A history of gestational diabetes is an important predictor of many metabolic disturbances later in life. Method. Life after gestational diabetes Ahvaz Study (LAGAs) is an ongoing population-based cohort study. Up to February 2016, 176 women with gestational diabetes underwent a 75 g oral glucose tolerance test (OGTT) at 6-12 weeks postpartum in Ahvaz (southwestern of Iran). Gestational diabetes was diagnosed according to the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria and the American Diabetes Association (ADA) criteria applied for diagnosis of postpartum prediabetes and diabetes. Univariate and multivariate regression analysis were done. Results. Overall incidence of early postpartum glucose intolerance was 22.2% (95% CI, 16.3-29.0), 17.6% prediabetes (95% CI, 12.3-24.1) and 4.5% diabetes (95% CI, 2.0-8.8%). Independent risk factors for glucose intolerance were FPG ≥ 100 at the time of OGTT (OR 3.86; 95% CI; 1.60-9.32), earlier diagnosis of GDM (OR 0.92; 95% CI; 0.88-0.97), systolic blood pressure (OR 1.02; 95% CI; 1.002-1.04), and insulin or metformin therapy (OR 3.14; 95% CI; 1.20-8.21). Conclusion. Results determined a relatively high rate of glucose intolerance at 6-12 weeks after GDM pregnancy. Early postpartum screening of type 2 diabetes is needed particularly in women at high risk of type 2 diabetes.


Assuntos
Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Gestacional/epidemiologia , Intolerância à Glucose/epidemiologia , Período Pós-Parto , Estado Pré-Diabético/epidemiologia , Adulto , Glicemia/metabolismo , Estudos de Coortes , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Gestacional/tratamento farmacológico , Diabetes Gestacional/metabolismo , Jejum , Feminino , Idade Gestacional , Intolerância à Glucose/metabolismo , Teste de Tolerância a Glucose , Humanos , Hiperglicemia/epidemiologia , Hiperglicemia/metabolismo , Hipoglicemiantes/uso terapêutico , Incidência , Insulina/uso terapêutico , Irã (Geográfico)/epidemiologia , Metformina/uso terapêutico , Estado Pré-Diabético/metabolismo , Gravidez , Fatores de Risco , Adulto Jovem
13.
Nephrol Dial Transplant ; 22(9): 2549-53, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17478487

RESUMO

BACKGROUND: Observations on the association between the ACE gene polymorphism and hypertension have been inconsistent, which might be due to ethnic and geographical variations. Moreover, the relationship between insertion/deletion (I/D) polymorphism and hypertension in the diabetic population has not been sufficiently studied. The aim of this study was to evaluate for the first time the possible association between I/D polymorphism and hypertension in an Iranian diabetic adult population. METHODS: A total of 82 consecutive patients with type 2 diabetes and hypertension (Group A) and 87 patients with type 2 diabetes but without hypertension (Group B) were included. Patients who had a history of hypertension before the onset of diabetes and those with findings suggesting secondary hypertension were excluded. The following variables were determined for each patient: age, sex, body mass index (BMI), diabetes duration and the drugs used, history of coronary artery disease and its complications, blood pressure (systolic and diastolic), fasting blood sugar (FBS), haemoglobin A1c (HbA1c), total cholesterol (Chol), low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides (TG), plasma creatinine (Crt) and 24 h urine albumin excretion. Polymerase chain reaction (PCR) was used to detect the I/D alleles. Univariate (chi-squared and t-test) and multivariate (multivariate binary logistic regression with adjusted odds ratios) analyses were applied to determine the association between I/D polymorphism (with genotype II as reference) and hypertension. P<0.05 was considered statistically significant. RESULTS: In univariate analysis, the groups were statistically similar in all variables except for diabetes duration (156.05+/-73.54 months in Group A vs 121.74+/-65.53 months in Group B; P=0.002), Crt (1.04+/-0.25 mg/dl in Group A vs 0.93+/-0.23 mg/dl in Group B; P=0.003), albuminuria (486.25+/-484.60 mg/d in Group A vs 316.50+/-459.56 mg/d in Group B; P=0.021) and the frequency of DD genotype (27 cases in Group A vs 11 cases in Group B; P=0.026). Multivariate logistic regression (using age, sex and BMI as clinically significant variables and diabetes duration, Crt, albuminuria and genotype as statistically significant variables) was then used to determine independent associations and adjusted odds ratios (OR). The DD genotype was the strongest independent predictor of hypertension [P=0.029, OR=3.122, 95% confidence interval (CI)=1.127-8.647], followed by log (albuminuria) (P=0.042, OR=1.183, 95% CI=1.006-1.391). Considering albuminuria as a categorical variable did not change the results significantly. CONCLUSION: The DD polymorphism in the ACE gene is independently associated with hypertension in the diabetic population.


Assuntos
Povo Asiático/genética , Diabetes Mellitus Tipo 2/complicações , Predisposição Genética para Doença , Hipertensão/complicações , Hipertensão/genética , Peptidil Dipeptidase A/genética , Polimorfismo Genético , Albuminúria , Feminino , Deleção de Genes , Humanos , Irã (Geográfico) , Masculino , Pessoa de Meia-Idade , Mutagênese Insercional , Análise de Regressão
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA